CSPG4 as Target for CAR-T-Cell Therapy of Various Tumor Entities–Merits and Challenges

Targeting cancer cells using chimeric-antigen-receptor (CAR-)T cells has propelled adoptive T-cell therapy (ATT) to the next level. A plentitude of durable complete responses using CD19-specific CAR-T cells in patients suffering from various lymphoid malignancies resulted in the approval by the food...

Descripción completa

Detalles Bibliográficos
Autores principales: Harrer, Dennis C., Dörrie, Jan, Schaft, Niels
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6928974/
https://www.ncbi.nlm.nih.gov/pubmed/31779130
http://dx.doi.org/10.3390/ijms20235942

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6928974/
https://www.ncbi.nlm.nih.gov/pubmed/31779130
http://dx.doi.org/10.3390/ijms20235942

Ejemplares similares